Matinas BioPharma Ends At-The-Market Sales Agreement with BTIG

What Happened
Matinas BioPharma Holdings, Inc. (MTNB) filed a Form 8-K reporting that BTIG, LLC notified the company it is terminating the At-The-Market Sales Agreement between the parties, effective immediately on July 23, 2026. The Sales Agreement was originally entered on July 2, 2020 and authorized at-the-market sales of up to $50,000,000 of Matinas common stock.

Key Details

• The Sales Agreement with BTIG permitted sales of Matinas common stock in at-the-market offerings totaling up to $50,000,000.
• BTIG delivered notice of termination under Section 12(a) of the agreement, effective July 23, 2026.
• The company stated it is not subject to any termination penalties or other expenses related to the termination.
• The Sales Agreement description is qualified by the copy filed as Exhibit 1.01 to Matinas’s July 2, 2020 Form 8-K.

Why It Matters
Termination of the agreement removes one existing channel Matinas used to sell shares into the market to raise equity capital. For investors, this is a material change to the company’s financing flexibility—though the filing notes no fees or penalties from the termination. The 8-K does not state any replacement arrangement or alternative financing plan.